Analyst picks & changes
Analysts reshuffled Biogen Inc. and Chiron Corp. in their portfolios following BGEN's announcement last week that it would file for marketing approval of its beta interferon for multiple sclerosis on the basis of its recently completed Phase III study.
, sold by Berlex and
